Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2015-12-03 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: GISORS (27140), Eure
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE VEYRON : revenue, balance sheet and financial ratios
SELARL PHARMACIE VEYRON is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in GISORS (27140),
this company of category PME
shows in 2022 a revenue of 5.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE VEYRON (SIREN 815066667)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
4 951 496 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
277 027 €
231 654 €
607 582 €
497 434 €
255 174 €
197 920 €
226 227 €
-68 988 €
-21 762 €
EBITDA
N/C
N/C
829 360 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
12.3%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE VEYRON generates positive net income of 277 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
277 027 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 216%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
215.85%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
28.13%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
2079.021
2961.656
928.212
535.106
355.161
195.075
133.816
229.751
215.85
Financial autonomy
4.233
2.753
8.492
14.258
19.549
29.122
37.017
26.743
28.13
Repayment capacity
None
None
None
None
None
None
3.632
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
12.522%
None%
None%
Sector positioning
Debt ratio
215.852024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average+11 pts over 3 years
In 2024, the debt ratio of SELARL PHARMACIE VEYRON (215.85) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
28.13%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch-12 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE VEYRON (28.1%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Repayment capacity
3.63 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of SELARL PHARMACIE VEYRON (3.63) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 195.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
259.801
121.291
145.169
154.755
164.843
183.414
209.412
247.637
195.654
Interest coverage
None
None
None
None
None
None
2.306
None
None
Sector positioning
Liquidity ratio
195.652024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of SELARL PHARMACIE VEYRON (195.65) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
2.31x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Average
In 2022, the interest coverage of SELARL PHARMACIE VEYRON (2.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE VEYRON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
720 789 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
30
0
0
Customer payment term (days)
0
0
0
0
0
0
13
0
0
Supplier payment term (days)
0
0
0
0
0
0
50
0
0
Positioning of SELARL PHARMACIE VEYRON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE VEYRON is estimated at
3 867 501 €
(range 2 693 267€ - 5 786 003€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
2693k€3867k€5786k€
3 867 501 €Range: 2 693 267€ - 5 786 003€
NAF 5 année 2024
Valuation method used
Net Income Multiple
277 027 €
×
14.0x
=3 867 502 €
Range: 2 693 267€ - 5 786 004€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE VEYRON with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE VEYRON
What is the revenue of SELARL PHARMACIE VEYRON ?
The revenue of SELARL PHARMACIE VEYRON in 2022 is 5.0 M€.
Is SELARL PHARMACIE VEYRON profitable?
Yes, SELARL PHARMACIE VEYRON generated a net profit of 277 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE VEYRON ?
The headquarters of SELARL PHARMACIE VEYRON is located in GISORS (27140), in the department Eure.
Where to find the tax return of SELARL PHARMACIE VEYRON ?
The tax return of SELARL PHARMACIE VEYRON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE VEYRON operate?
SELARL PHARMACIE VEYRON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart